Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

The hold will help ADXS negotiate a bigger deal for AXAL because the FDA likely initiated the hold because it is about to grant AXAL early approval and just wanted to make sure Berlin crossed the Is and dotted the Ts beforehand. Therefore, I expect the deal we are about to see will command $200 million upfront. Berlin, enough already, announce the cancellation of the reverse and dilution. With AXAL approval coming soon, ADXS is in a position of strength. GLTA